Agile Therapeutics

Agile Therapeutics is the pharmaceutical company developing contraceptive healthcare products for women. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive patch.

In addition to Twirla, Agile is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of the Company's product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Company Growth (employees)
Type
Public
HQ
Princeton, US
Founded
1997
Size (employees)
17 (est)-5%
Agile Therapeutics was founded in 1997 and is headquartered in Princeton, US

Key People at Agile Therapeutics

Al Altomari

Al Altomari

President & CEO & Board ofDirectors
Scott Coiante

Scott Coiante

Chief Financial Officer
C.Gregory Arnold

C.Gregory Arnold

Vice President of Manufacturing
Robert G.Conway

Robert G.Conway

Chief Development Officer, Vice President, Operations
Elizabeth Garner

Elizabeth Garner

Senior Vice President and Chief Medical Officer

Agile Therapeutics Office Locations

Agile Therapeutics has an office in Princeton
Princeton, US (HQ)
101 Poor Farm Rd

Agile Therapeutics Data and Metrics

Agile Therapeutics Financial Metrics

USD

Net income (Q1, 2017)

(7.5 m)

EBIT (Q1, 2017)

(7.1 m)

Market capitalization (17-Aug-2017)

100.2 m

Cash (31-Mar-2017)

41.7 m
Agile Therapeutics's current market capitalization is $100.2 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

13.4 m25.6 m20.9 m

General and administrative expense

5.2 m7.5 m8.8 m

Operating expense total

18.5 m33.1 m29.7 m

EBIT

(18.5 m)(33.1 m)(29.7 m)

Interest expense

(1.6 m)(2.1 m)(2.4 m)

Interest income

2.6 k5 k117 k

Net Income

(16.1 m)(30.3 m)(28.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

2.4 m4.6 m5.4 m6.2 m7.2 m4.9 m5.6 m4.9 m4.7 m

General and administrative expense

1.1 m1.4 m1.6 m1.8 m1.8 m2.1 m2.3 m2.2 m2.4 m

Operating expense total

3.5 m6 m7 m8 m9 m7 m7.8 m7.1 m7.1 m

EBIT

(3.5 m)(6 m)(7 m)(8 m)(9 m)(7 m)(7.8 m)(7.1 m)(7.1 m)

Interest expense

(403.5 k)(392 k)(425.8 k)(547.6 k)(551.7 k)(548 k)(548 k)(784 k)(546 k)

Interest income

821.3 k1.2 k1.3 k1.2 k17 k33 k33 k47 k

Net Income

(2.9 m)(9.2 m)(8.5 m)(17 m)(26.4 m)(7.3 m)(15.7 m)(23.5 m)(7.5 m)
USDFY, 2014FY, 2015FY, 2016

Cash

40.2 m34.4 m48.8 m

Accounts Receivable

539 m

Current Assets

41 m38.1 m51.5 m

PP&E

12 m12.3 m12.3 m

Total Assets

54.8 m50.7 m63.9 m

Accounts Payable

2.6 m2.4 m2.1 m

Current Liabilities

9 m7.9 m10.7 m

Additional Paid-in Capital

170.4 m194.5 m235.8 m

Retained Earnings

(134.4 m)(164.7 m)(193.5 m)

Total Equity

36 m29.7 m42.3 m

Financial Leverage

1.5 x1.7 x1.5 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

53.5 m45.7 m53.9 m46.4 m39.4 m65.5 m59.2 m51.7 m41.7 m

Current Assets

54.2 m47 m54.4 m47.2 m40.7 m68.5 m61.3 m54.8 m44.3 m

PP&E

12.3 m12.3 m12.3 m12.3 m

Total Assets

66.3 m60.9 m68.7 m61.7 m55.1 m80.9 m73.6 m67.1 m56.6 m

Accounts Payable

2.3 m2.7 m3.3 m2.7 m4.3 m2.9 m3 m2.9 m3.2 m

Current Liabilities

5.3 m7.2 m4.8 m5.2 m6.9 m8.4 m10.1 m8.4 m11.6 m

Additional Paid-in Capital

169.5 m169.9 m191.7 m192.6 m193.6 m233 m234 m234.9 m236.6 m

Retained Earnings

(121.2 m)(127.5 m)(142.9 m)(151.4 m)(160.8 m)(172 m)(180.5 m)(188.3 m)(201 m)

Total Equity

48.8 m41.2 m32.7 m61 m53.5 m46.7 m35.6 m

Financial Leverage

1.4 x1.5 x1.7 x1.3 x1.4 x1.4 x1.6 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(16.1 m)(30.3 m)(28.7 m)

Depreciation and Amortization

12.6 k18 k19 k

Inventories

(2.3 m)(1.2 m)922 k

Accounts Payable

2.6 m1.3 m362 k

Cash From Operating Activities

(14.5 m)(25.5 m)(23.3 m)

Purchases of PP&E

(95.7 k)(290 k)(31 k)

Cash From Investing Activities

(95.7 k)(290 k)(31 k)

Cash From Financing Activities

52.7 m20 m37.7 m

Interest Paid

1.4 m1.5 m1.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.9 m)(9.2 m)(8.5 m)(17 m)(26.4 m)(7.3 m)(15.7 m)(23.5 m)(7.5 m)

Depreciation and Amortization

5 k7.7 k5 k10.1 k14.3 k4 k9 k14 k5 k

Accounts Payable

1.6 m2.2 m724.3 k1.2 m3 m(771 k)(768 k)(648 k)348 k

Cash From Operating Activities

(5.6 m)(13.2 m)(20.4 m)(6.7 m)(13 m)(20.4 m)(6 m)

Purchases of PP&E

(6.7 k)(42.3 k)(188.6 k)(274.1 k)(288.4 k)(2 k)(20 k)(25 k)(5 k)

Cash From Investing Activities

(6.7 k)(42.3 k)(188.6 k)(274.1 k)(288.4 k)(2 k)(20 k)(25 k)(5 k)

Long-term Borrowings

(15.8 m)(15.8 m)(15.8 m)(993 k)

Cash From Financing Activities

52.6 m52.6 m19.5 m19.7 m19.9 m37.8 m37.8 m37.7 m(993 k)

Interest Paid

690 k1 m339.3 k718.8 k1.1 m375 k755 k1.1 m368 k
Y, 2017

Financial Leverage

1.6 x

Agile Therapeutics Operating Metrics

FY, 2016

Phase III Trials

1

Phase II Trials

1

Phase I Trials

3

Patents (US)

13

Patents (foreign)

45

Agile Therapeutics Market Value History

Traffic Overview of Agile Therapeutics

Agile Therapeutics Company Life and Culture

You may also be interested in